Cell-free DNA purification upgrade, 3/16
March 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multi-template analysis LiquidBiopsy platform.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
NGS HLA typing solution, 3/16
March 2016—Immucor, in collaboration with Sirona Genomics, announced the launch of Mia Fora NGS, a high-resolution human leukocyte antigen typing solution that provides accurate, comprehensive coverage of 11 HLA genes. With a workflow that can be automated or run manually, Mia Fora NGS is adapted for use on the Illumina MiSeq next-generation sequencing platform and is available for research use only in the U.S. and other countries, with CE mark anticipated shortly.
Chembio to sell its Sure Check HIV 1/2 Assay, 3/16
March 2016—Chembio Diagnostics will begin selling its Sure Check HIV 1/2 Assay in the U.S. market on June 1. The product is currently distributed in the United States by Alere under Alere’s Clearview Complete brand, and Chembio has notified Alere that it will not renew or extend the distribution agreement when it terminates on May 31.
High-capacity FISH hybridization system, 3/16
March 2016—SciGene introduced a high-capacity system for performing FISH hybridization assays. The system consists of one CytoBrite Slide Incubation System for performing rapid probe denaturation on batches of 12 FISH slides and one CytoBrite Slide Oven for overnight hybridizations of 60 slides. Removable slide trays streamline slide setup and transfers between instruments.
Sakura Finetek acquires Genemed, 3/16
March 2016—Sakura Finetek USA announced the acquisition of Genemed Biotechnologies’ tissue-based advanced staining business for cancer detection, diagnosis, and monitoring. Genemed’s liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business.
Multiplex TTF-1 and cytokeratin 5 cocktail, 3/16
March 2016—ScyTek Laboratories announced the availability of its Multiplex TTF-1 and Cytokeratin 5 Cocktail. This multiplex cocktail of TTF-1 and cytokeratin 5 produces two-color, high-contrast staining for differentiating primary adenocarcinoma of the lung from metastatic carcinomas of the breast and malignant mesothelioma. This cocktail can increase sensitivity and diagnostic utility in differential diagnosis of the tumor.
PerkinElmer acquires Vanadis, 3/16
March 2016—PerkinElmer has acquired Vanadis Diagnostics. Based in Sweden, Vanadis is developing a novel solution for non-invasive prenatal testing based on digital analysis of cell-free DNA.
Image analysis software, 3/16
March 2016—Definiens released its Tissue Studio 4.2 software package. The updated product suites provide improved image analysis functionality for scientists in academic medical centers, comprehensive cancer centers, and biotech and pharmaceutical companies.
CE marking for pneumonia FIA, 3/16
March 2016—Quidel has received the CE mark for its Sofia S. pneumoniae fluorescent immunoassay for use with the Sofia Fluorescent Immunoassay Analyzer. The Sofia S. pneumoniae FIA enables the qualitative detection of Streptococcus pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid of patients with meningitis in 10 minutes.
NanoString collaboration with Medivation, Astellas, 3/16
March 2016—Medivation and NanoString Technologies have entered into a collaboration, together with Astellas Pharma, to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString’s nCounter Dx Analysis System.